Application of nerve guiding factor Sema3A and pharmaceutical composition for treating osteolysis

The invention belongs to the technical field of biological medicine, and particularly relates to application of a nerve guiding factor Sema3A and a pharmaceutical composition for treating osteolysis. By injecting Sema3A overexpressed virus or recombinant Sema3A protein into the tibia of an osteolysis mouse model, it is proved that Sema3A overexpressed or recombinant protein can effectively inhibit osteolysis and proliferation of lymphatic endothelial cells in bones, it is indicated that Sema3A has the effect of reducing osteolysis symptoms, and it is indicated that Sema3A can serve as a target spot to treat osteolysis. Furthermore, various physical and physiological feature changes of the tibia of the Sema3A knock-down model group and the tibia of the control group are compared, it is found that in the mouse tibia, the Sema3A knock-down model group has obvious osteolysis symptoms compared with the control group, and the Sema3A knock-down model can be applied to research on pathogenesis and treatment of osteol